National Institutes of Health

Neurodon Corporation is a biopharmaceutical company focused on discovering and developing disease-modifying therapeutic candidates for intractable diseases. Established in 2019 and headquartered in Crown Point, Indiana, Neurodon specializes in molecular therapies that address endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach aims to restore calcium homeostasis through first-in-class modulators, addressing conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, and other rare diseases. Neurodon has made significant progress, with two candidates currently in IND-enabling studies and plans to enter clinical trials in 2025. The company has raised over $11 million through various funding sources, including state and federal grants, partnerships, and angel investments, and is actively seeking additional funding to support its first human studies for diabetes and rare disease programs.

The Indiana CTSI is dedicated to leveraging and strengthening the state’s life sciences community to achieve better health for people in Indiana.Leadership and staff at the Indiana CTSI are working to develop the best processes and resources to enable the efficient translation of scientific discoveries to patient care.Indiana CTSI programs and partnerships are designed to educate, attract and retain top research talent in the state for generations to come.

The Indiana University School of Medicine is the largest medical school in the United States. The IU School of Medicine, which is made up of five fundamental science departments and twenty clinical departments, provides superior training for students interested in pursuing a medical degree. The school launched a new medical education curriculum with the Class of 2020 that better represents the modern U.S. health care environment and delivery methods, preparing students to practice medicine in a team-based, multidisciplinary setting.

Founded in 1820, Indiana University Bloomington is a public research-intensive university committed to liberal arts and sciences education. It offers professional, medical, and technological programs, aiming to create, disseminate, preserve, and apply knowledge through cutting-edge research, scholarship, and creative activity.

Neurodon Corporation is a biopharmaceutical company focused on discovering and developing disease-modifying therapeutic candidates for intractable diseases. Established in 2019 and headquartered in Crown Point, Indiana, Neurodon specializes in molecular therapies that address endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach aims to restore calcium homeostasis through first-in-class modulators, addressing conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, and other rare diseases. Neurodon has made significant progress, with two candidates currently in IND-enabling studies and plans to enter clinical trials in 2025. The company has raised over $11 million through various funding sources, including state and federal grants, partnerships, and angel investments, and is actively seeking additional funding to support its first human studies for diabetes and rare disease programs.

Founded in 2008 by Dr. Michela Gallagher, AgeneBio is a neuroscience pharmaceutical company dedicated to developing treatments for memory disorders. Its primary focus is on Amnestic Mild Cognitive Impairment (aMCI) and Alzheimer's disease (AD), aiming to prevent neurodegeneration and preserve cognitive function.

Founded in 2013, Recovery Force is a digital health company specializing in wearable medical technology. It manufactures and supplies healthcare apparel, including sleeves and shoes, designed to enhance circulation, reduce post-operative pain, and improve patient mobility.

Founded in 2008 by Dr. Michela Gallagher, AgeneBio is a neuroscience pharmaceutical company dedicated to developing treatments for memory disorders. Its primary focus is on Amnestic Mild Cognitive Impairment (aMCI) and Alzheimer's disease (AD), aiming to prevent neurodegeneration and preserve cognitive function.

Novosteo Inc. is a biotechnology company based in West Lafayette, Indiana, founded in 2017. The firm specializes in developing and manufacturing innovative drugs aimed at healing bone fractures and addressing related conditions that significantly impact patients' morbidity, mortality, and quality of life. With scientific guidance from co-founders Stewart Low and Philip Low of Purdue University, Novosteo utilizes a proprietary chemistry approach to bone targeting, which allows for the delivery of anabolic agents directly to fracture surfaces. This unique method focuses on accelerating bone regeneration and improving healing outcomes, thereby mitigating the debilitating effects associated with bone injuries and enhancing patient mobility and productivity.

Neurodon Corporation is a biopharmaceutical company focused on discovering and developing disease-modifying therapeutic candidates for intractable diseases. Established in 2019 and headquartered in Crown Point, Indiana, Neurodon specializes in molecular therapies that address endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach aims to restore calcium homeostasis through first-in-class modulators, addressing conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, and other rare diseases. Neurodon has made significant progress, with two candidates currently in IND-enabling studies and plans to enter clinical trials in 2025. The company has raised over $11 million through various funding sources, including state and federal grants, partnerships, and angel investments, and is actively seeking additional funding to support its first human studies for diabetes and rare disease programs.

The Indiana CTSI is dedicated to leveraging and strengthening the state’s life sciences community to achieve better health for people in Indiana.Leadership and staff at the Indiana CTSI are working to develop the best processes and resources to enable the efficient translation of scientific discoveries to patient care.Indiana CTSI programs and partnerships are designed to educate, attract and retain top research talent in the state for generations to come.

Fast Biomedical is a clinical-stage medical technology company based in Indiana, dedicated to the development and commercialization of an innovative technology for quantifying critical health parameters that have historically been difficult to measure. The company's primary focus is on assessing blood volume and kidney function in a clinically viable manner. Fast Biomedical's technology utilizes a fluorescent compound to enhance the detection of kidney infections, allowing for faster identification of acute kidney failure compared to traditional lab tests. By injecting markers into a patient's bloodstream that fluoresce when analyzed with their device, physicians can more effectively monitor kidney health and improve patient outcomes.

Founded in 1820, Indiana University Bloomington is a public research-intensive university committed to liberal arts and sciences education. It offers professional, medical, and technological programs, aiming to create, disseminate, preserve, and apply knowledge through cutting-edge research, scholarship, and creative activity.

SpeechVive Inc. is a medical device company developing a wearable speech device to assist people with Parkinson's disease by improving speech and communication. Founded in 2011 and based in Lafayette, Indiana, the company aims to enhance speech volume and clarity for daily life. The device is designed to suppress ambient background sound, which helps users hear themselves more clearly and speak more effectively, addressing communication challenges associated with Parkinson's disease.

KinaSense LLC is a biotechnology company focused on developing innovative products for cancer drug testing during the pre-clinical and clinical phases of drug discovery. Based in West Lafayette, Indiana, the company specializes in cancer diagnostic solutions and drug discovery technologies, particularly in the area of tyrosine kinase inhibitors (TKIs), which are employed in treating various cancer types. KinaSense aims to enhance the predictive capabilities of current diagnostic tools, enabling healthcare providers to match patients more effectively with the appropriate TKIs based on individual responses. Through its assays and cell-based kits, KinaSense is committed to improving patient outcomes by facilitating personalized care tailored to the specific efficacy and selectivity of TKIs. Established in 2013, the company continues to focus on advancing cancer treatment through its innovative approaches.